Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections

Size: px
Start display at page:

Download "Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections"

Transcription

1 Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver Health q Durata Therapeutics Disclosure of off-label drug uses q Trimethoprim-sulfamethoxazole, clindamycin, doxycycline

2 q q q Explain the evolving epidemiology and microbiology of skin infections Identify recent evidence regarding the diagnosis, treatment, and prevention of common skin infections Implement strategies to improve the management of skin infections in clinical practice Goals for 2020: Establishment of antibiotic stewardship programs in all acute care hospitals Reduce inappropriate antibiotic use by 20% in hospitals Optimizing antibiotic use for each patient to: q q Maximize the chance for a good clinical outcome AND Minimize unintended consequences of antibiotics Selection of resistant organisms C. difficile infection Adverse drug events Drug interactions Microbiome disruption Health care costs

3 1488 adults with 24 hours of IV or oral antibiotic exposure at Johns Hopkins Hospital 298 (20%) 1 antibiotic-associated adverse event 42% gastrointestinal 24% renal 15% hematologic 287 (19%) antibiotic regimens not clinically indicated 20% associated with adverse event Tamma P. JAMA Intern Med 2017; 177:1308 Question 1 65yo man presents with severe right thigh pain since striking his thigh on a countertop yesterday. He has a history of pulmonary embolus for which he takes warfarin. One week ago he was hospitalized for a left arm abscess. After drainage and IV antibiotics, he was discharged with a 10-day course of an unknown antibiotic. There is a large area of induration and ecchymosis over the thigh. Ultrasound shows a large hematoma. His INR is 8.6. He denies any change in his warfarin dose or dietary changes. Which antibiotic had he most likely been prescribed? A. Clindamycin B. Doxycycline C. Trimethoprim-sulfamethoxazole D. Cephalexin

4 Epidemiology and microbiology Magill S. JAMA 2014; 312:1438 Hospital admission and mortality rates for skin infections, Kaye KS et al. PLoS ONE 2015;10:e

5 Microbiology of inpatient skin infections 533 cases of cellulitis, wound infection, or abscess from 7 Colorado hospitals N =533 Any microorganism identified 202 (38) Any gram-positive pathogen 190 (94) Staphylococcus aureus 127 (63) MSSA 58 (29) MRSA 64 (32) Streptococcal species 59 (29) Aerobic gram-negative organism 20 (10) Only gram-negative organism(s) identified 4 (2) Anaerobic organism(s) 17 (8) Jenkins T. Infect Control Hosp Epidemiol 2014; 35:1241 Microbiology of cellulitis in era of CA-MRSA q 2 studies of >200 patients hospitalized for cellulitis (California 1 and Norway 2 ) q 3/4 confirmed etiology of β-hemolytic streptococci by serology or culture q Of patients only treated with β-lactam antibiotic, 96% cured 1 1) Jeng A. Medicine 2010; 89: ) Bruun T. Open Forum Infect Dis 2017 Diagnosis of cellulitis

6 Question 2 56yo obese woman admitted with 2 days of progressive bilateral lower extremity redness, swelling, and pain. She has been fatigued but denies fever, chills, feeling ill, SOB, or CP. She had a LLE DVT 3 months prior for which she is on rivaroxaban. On exam she has bilateral erythema from the ankles to the mid-calf (more intense on the left) with edema and tenderness to palpation. There is scaling skin over the shins and patchy hyperpigmentation. What is the most appropriate next step? A. Order a LLE ultrasound B. Obtain Dermatology consultation C. Start vancomycin D. Start cefazolin Frequent misdiagnosis of cellulitis Adapted from Weng QY. JAMA Dermatol 2017; 153:141

7 Raff AB. JAMA 2016; 316:325 Beware of pseudocellulitis Know common causes: Stasis dermatitis Contact dermatitis Insect bite reaction Gout Hematoma Deep venous thrombosis Antibiotics and skin abscesses Question 3 A 22yo healthy man you are seeing in the ED has a 3x4cm left upper extremity skin abscess. He notes several members of his wrestling team have had similar infections recently. The abscess is incised and 2cc of pus is drained. What is the most appropriate antibiotic therapy? A. Trimethoprim-sulfamethoxazole B. Doxycycline C. Cephalexin D. No antibiotic is necessary

8 Infectious Diseases Society of America guideline for management of skin infections Give antibiotics after abscess drainage if: Fever Other evidence of systemic involvement Markedly impaired host defenses Inadequate response to drainage alone Stevens D. Clin Infect Dis 2014;59:e10-e participants (281 children) with abscess 5cm Randomized to 10 days of: Clindamycin 300mg TID TMP-SMX 1DS BID Placebo Daum RS. NEJM 2017; 376: 2545 Clinical cure 7 10 days after end of treatment in the intention to treat population Clindamycin % TMP-SMX % Placebo % All participants* Children Adults S. aureus isolated No S. aureus isolated Primary outcome *p<.001 for difference between clindamycin and placebo and between TMP-SMX and placebo NNT = 7 to prevent one clinical failure

9 Adverse events Clindamycin % TMP-SMX % Placebo % Any adverse event Diarrhea Nausea patient in TMP-SMX group had serious antibiotic-related adverse event (hypersensitivity reaction) Retrospective analysis of 269 patients hospitalized for cellulitis or abscess Compared outcomes between: Vancomycin alone Vancomycin plus clindamycin Wargo K. Clin Infect Dis 2015 ;61:1148 Primary outcome Hospital length of stay in days Vancomycin monotherapy Vancomycin and clindamycin All cases (mean ± SD) 4.0 ± ± Abscesses only 4.4 ± ± P Clindamycin group: 18% reduction in LOS after adjustment for treatment, I&D status, diabetes, outpatient antibiotics, and corticosteroid therapy

10 Summary Antibiotics and skin abscesses q Antibiotics after abscess drainage in outpatients improves outcomes q Benefit seen in S. aureus abscesses q Clindamycin less well tolerated than TMP-SMX q Whether adjunctive clindamycin for inpatients improves outcomes requires further study Antibiotic choice for cellulitis Question 4 45yo woman presents complaining of RLE erythema, swelling, and pain that began suddenly 12 hours ago. She is unable to bear weight due to the pain. She has a long history of poorly controlled diabetes mellitus (A1C 10.2). Her temperature is 38.7C and she has findings consistent with RLE cellulitis. There is no wound, purulence, or evidence of abscess. She has tinea pedis and onychomycosis.

11 What is the most appropriate initial therapy? A. Cefazolin B. Vancomycin C. Vancomycin + piperacillin-tazobactam D. Vancomycin + clindamycin Antibiotic selection for cellulitis q q q Uncertainty regarding optimal treatment since emergence of CA-MRSA In vitro and observational data suggest MRSA-active agents (TMP-SMX, doxycycline) not adequate for β- hemolytic streptococci Combination of β-lactam plus MRSA-active agent has become common practice (~15% of cases) 1,2 1) Hurley H. Am J Med 2013; 126; ) Jenkins T. Infect Control Hosp Epi 2014; 35:1241 Stevens D. Clin Infect Dis 2014; 59:e10-52

12 410 outpatients or inpatients from 20 hospitals in England with lower extremity cellulitis Randomized to: Flucloxacillin 500mg PO or IV QID 5 days + Clindamycin 300mg PO TID x 2 days Flucloxacillin + placebo BMJ Open 2017; 7:e Outcomes Clinical improvement defined as afebrile and reduction in swelling or erythema at day 5 Incidence of diarrhea at day 10: 12.8% with clindamycin vs 5.3% with placebo (p =.04) 500 patients >12 years old with cellulitis (no wound or purulence) randomized to 7 days of: Cephalexin 500mg QID + TMP-SMX 2DS BID Cephalexin + placebo JAMA 2017; 317:2088

13 Outcomes and adverse events Clinical cure in 83.5% (TMP-SMX) vs. 85.5% (placebo) No significant difference in any secondary outcome: Need for hospitalization Recurrent or new site of skin infection Missed days or normal activity or school/work Days of pain medication Treatment-related adverse event: 42% (TMP-SMX) vs. 36% (placebo) Gastrointestinal disorder: 46% (TMP-SMX) vs. 39% (placebo) 524 patients with abscess (>5cm diameter), cellulitis, or both Randomized to: Clindamycin 300mg TID x 10 days TMP/SMX 1DS BID x 10 days Miller L. NEJM 2015; 372:1093 Cure rate Clindamycin group TMP-SMX group P All patients Intention to treat 212/264 (80%) 202/260 (78%).52 Per protocol population 212/237 (90%) 202/229 (88%).77 Cellulitis without abscess Intention to treat 110/136 (81%) 110/144 (76%).38 Per protocol population 110/121 (91%) 110/127 (87%).32 Adapted from Miller L. NEJM 2015; 372:1093

14 Summary Antibiotic selection for cellulitis q National guidelines recommend β-lactam monotherapy q Addition of MRSA-active agent to a β-lactam does not improve outcomes q Increased risk of adverse outcomes with addition of clindamycin q TMP-SMX is a reasonable treatment option for non-purulent cellulitis Duration of therapy Question 4 continued Your patient s cellulitis has markedly improved after 2 days of cefazolin. She states she is leaving the day after tomorrow for a 10-day family vacation to Cancun, Mexico. When writing your discharge prescription, what total duration of therapy should be completed? A. 5 days B. 7 days C. 10 days D. 14 days

15 Duration of therapy for cellulitis Randomized trial of 5 vs 10 days of levofloxacin for cellulitis Signs/symptoms scores at follow up (n = 87) 98% in each group had resolution of symptoms within 14 days and absence of relapse within 28 days (p >.05) Hepburn M. Arch Int Med 2004; 164:1669 Randomized trial of tedizolid for 6 days vs. linezolid for 10 days *Tedizolid non-inferior at both time points Prokocimer P. JAMA 2013; 309:559 IDSA guideline recommendations Duration of therapy Cellulitis q 5 days if clinically responding (strong recommendation, high-quality evidence) Cutaneous abscess q No specific recommendations Stevens D. Clin Infect Dis 2014; 59:e10

16 Summary of IDSA guideline treatment recommendations Short course of a single antibiotic targeted toward gram-positive pathogens Stevens D. Clin Infect Dis 2014; 59:e10-52 Single-dose treatment of skin infections Oritavancin and dalbavancin q Lipoglycopeptides with prolonged half-life à once-weekly dosing q Single dose as effective as 7-14 day courses of vancomycin and/or linezolid q Very expensive q Role to shorten or avoid hospitalization? Corey GR. NEJM 2014; 370:2180 Boucher HW. NEJM 2014; 370:2169 Dunne MW. Clin Infect Dis 2016; 62:545 Summary Duration of therapy q Existing evidence suggests prolonged antibiotic therapy does not improve outcomes q National guidelines support short courses of therapy q Role of long half-life agents unclear

17 Question 5 59yo man is hospitalized with his third episode of RLE cellulitis in the last 6 months. The prior two episodes completely resolved with appropriate short courses of beta-lactam therapy. On exam he has cellulitis without purulent drainage or abscess. There are no wounds, excoriations, skin changes suggestive of venous stasis, or tinea pedis. You start cefazolin and he improves over the next several days. What is the most appropriate discharge therapy? A. Cephalexin to complete 5-day course B. Complete cephalexin course then start longterm oral penicillin C. Complete cephalexin course then perform S. aureus decolonization D. Cephalexin to complete 14-day course Prevention of recurrent infections

18 274 patients with 2 episodes of lower extremity cellulitis Randomized to 12 months of: PCN 250mg PO BID Placebo NEJM 2013; 368:1695 Proportion of patients recurrence-free over time Thomas KS. NEJM 2013; 368:1695

19 Goals for 2020: Establishment of antibiotic stewardship programs in all acute care hospitals Reduce inappropriate antibiotic use by 20% in hospitals Broad-spectrum antibiotic use before and after the intervention Jenkins T. Arch Int Med 2011; 171:1072 Duration of therapy before and after the intervention Median duration of therapy decreased from 13 days to 10 days (p <.001)

20 q Ensure correct diagnosis q Appropriate spectrum of antibiotics Cellulitis: cefazolin monotherapy Abscess: MRSA-active agent q Short durations of therapy q Prevent infections Questions? timothy.jenkins@dhha.org

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know 2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2

More information

Le infezioni di cute e tessuti molli

Le infezioni di cute e tessuti molli Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections

More information

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1 Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director

More information

Staph Cases. Case #1

Staph Cases. Case #1 Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

Antibiotic Updates: Part I

Antibiotic Updates: Part I Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

New Antibiotics for MRSA

New Antibiotics for MRSA New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker

More information

Optimizing Antibiotic Stewardship in the ED

Optimizing Antibiotic Stewardship in the ED Optimizing Antibiotic Stewardship in the ED Michael Pulia, MD MS FAAEM FACEP Director, UW EM Antibiotic Stewardship Research Program Chair, AAEM Antimicrobial Stewardship Task Force @DrMichaelPulia Learning

More information

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018 Cellulitis Assoc Prof Mark Thomas Conference for General Practice Auckland Saturday 28 July 2018 Summary Cellulitis Usual treatment flucloxacillin for 5 days Frequent recurrences consider penicillin 250mg

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Discussion Points. Decisions in Selecting Antibiotics

Discussion Points. Decisions in Selecting Antibiotics Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical

More information

S aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium

S aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of

More information

SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015

SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015 SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015 Disclosures I have no financial conflicts of interest to disclose or report. Steven Tran, PharmD NEFSHP Fall Meeting 2015 Objectives for Pharmacists Review

More information

Overview Management of Skin and Soft Tissue Infections in the MRSA Era

Overview Management of Skin and Soft Tissue Infections in the MRSA Era Overview Management of Skin and Soft Tissue Infections in the MRSA Era April 2011 2011 IDSA MRSA Treatment Guidelines Skin and soft tissue infections (SSTIs) Management of Recurrent SSTIs Necrotizing soft

More information

High Risk Emergency Medicine. Antibiotic Pitfalls

High Risk Emergency Medicine. Antibiotic Pitfalls High Risk Emergency Medicine Antibiotic Pitfalls David, MD MS Assistant Professor Department of Emergency Medicine University of California, San Francisco I. Antibiotic Resistance Development of resistance

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Infectious Disease Update 2017

Infectious Disease Update 2017 Infectious Disease Update 2017 Greg Moran, MD, FACEP, FIDSA Professor of Clinical Emergency Medicine Geffen School of Medicine at UCLA Dept. of Emergency Medicine and Division of Infectious Diseases Olive

More information

Antibiotic Stewardship

Antibiotic Stewardship Antibiotic Stewardship Nick Zaksek Pharm D., BCPS AQ-ID Infectious Disease POMA 2019 1 Disclosures None 2 Objectives Practice good Antibiotic stewardship and foster the notion of antibiotic stewardship

More information

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection

More information

Mrsa abscess and cellulitis

Mrsa abscess and cellulitis Search Mrsa abscess and cellulitis An abscess is a collection of pus that has built up within the tissue of the body. Signs and symptoms of abscesses include redness, pain, warmth, and swelling. The. Staph

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 3 PURPOSE To assure that DOP inmates with Soft Tissue Infections are receiving high quality Primary Care for their infections and that the risk of infecting other inmates or staff is minimized.

More information

Replaces:04/14/16. Formulated: 1997 SKIN AND SOFT TISSUE INFECTION

Replaces:04/14/16. Formulated: 1997 SKIN AND SOFT TISSUE INFECTION Effective Date: 04/13/17 Replaces:04/14/16 Page 1 of 7 POLICY To standardize the clinical management and housing of offenders with skin and soft tissue infections, thereby reducing the transmission and

More information

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

LINEE GUIDA: VALORI E LIMITI

LINEE GUIDA: VALORI E LIMITI Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions

More information

Antibiotic Duration for Common Infections

Antibiotic Duration for Common Infections Antibiotic Duration for Common Infections Emily Spivak, MD, MHS Division of Infectious Diseases Medical Director, Antimicrobial Stewardship Program University of Utah Hospitals and Clinics Learning Objectives

More information

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of

More information

Antimicrobial Stewardship in Ambulatory Care

Antimicrobial Stewardship in Ambulatory Care Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative

More information

Tropical infections caused by Staphylococcus aureus

Tropical infections caused by Staphylococcus aureus Tropical infections caused by Staphylococcus aureus Michael Ellis, MD Infectious Diseases Division Uniformed Services University of the Health Sciences February 2015 Introduction Tropical Pyomyositis Cutaneous

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally

10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally

More information

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,

More information

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare 100% of all wounds will yield growth If you get a negative culture you something is wrong! Pseudomonas while ubiquitous does

More information

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Eileen M. Bulger, MD Professor of Surgery Harborview Medical Center University of Washington Objectives Review definition & diagnostic

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

MRSA What Are Our Treatment Options and How Do We Choose the Right One?

MRSA What Are Our Treatment Options and How Do We Choose the Right One? MRSA What Are Our Treatment Options and How Do We Choose the Right One? Kristi Traugott, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases University Health System San Antonio, TX October 25,

More information

ANTIBIOTICS IN THE ER:

ANTIBIOTICS IN THE ER: ANTIBIOTICS IN THE ER: EXPLORING THE ROLE OF ANTIMICROBIAL STEWARDSHIP IN THE EMERGENCY DEPARTMENT ANGELINA DAVIS, PHARMD, MS, BCPS (AQ-ID) LIAISON CLINICAL PHARMACIST DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH

More information

MRSA Background. New Challenges From an Old Foe. MRSA Demographics. Comparison of Types of MRSA CA-MRSA HA-MRSA

MRSA Background. New Challenges From an Old Foe. MRSA Demographics. Comparison of Types of MRSA CA-MRSA HA-MRSA Winter Clinical 2017 : MRSA Update Whitney A. High, MD, JD, Meng whitney.high@ucdenver.edu Associate Professor, Dermatology & Pathology Director of Dermatopathology University of Colorado School of Medicine

More information

Clinical Practice Standard

Clinical Practice Standard Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:

More information

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives

More information

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

Development of Drugs for Skin Infections

Development of Drugs for Skin Infections EFPIA - Skin Infection comments 1 Development of Drugs for Skin Infections John H Rex, MD EFPIA - Skin Infection comments 2 Skin Infections Significant recent debate: Acceptable forms: A focus on fever

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

CLINICAL USE OF BETA-LACTAMS

CLINICAL USE OF BETA-LACTAMS CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial

More information

Infections caused by Methicillin-Resistant Staphylococcus

Infections caused by Methicillin-Resistant Staphylococcus MRSA infections are no longer limited to hospitals. An infectious disease specialist offers insight on what this means for dermatologists. By Robert S. Jones, DO, Reading, PA Infections caused by Methicillin-Resistant

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

New Antibiotics & New Insights into Old Antibiotics

New Antibiotics & New Insights into Old Antibiotics New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections.

48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections. 48 th Annual Meeting IDWeek and ICAAC: The Cliffs Notes Version Yanina Pasikhova Pharm.D., BCPS-AQ ID, AAHIVP Infectious Diseases Pharmacist Moffitt Cancer Center Navigating the Oceans of Opportunity Skin

More information

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.

More information

Bacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups

Bacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a

More information

Community Methicillin- Resistant Staphylococcus aureus. Sixth Plague of Egypt. Epidemiology

Community Methicillin- Resistant Staphylococcus aureus. Sixth Plague of Egypt. Epidemiology Community Methicillin- Resistant Staphylococcus aureus Henry F. Chambers, M.D. University of California San Francisco San Francisco General Hospital Sixth Plague of Egypt (~ 1200 BCE) So they took soot

More information

Safety of an Out-Patient Intravenous Antibiotics Programme

Safety of an Out-Patient Intravenous Antibiotics Programme Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds

More information

Evaluation of Physician Prescribing Patterns For Antibiotics in the Treatment of Nonnecrotizing Skin and Soft Tissue Infections

Evaluation of Physician Prescribing Patterns For Antibiotics in the Treatment of Nonnecrotizing Skin and Soft Tissue Infections Evaluation of Physician Prescribing Patterns For Antibiotics in the Treatment of Nonnecrotizing Skin and Soft Tissue Infections Michael C. Ezebuenyi, PharmD, BCPS; Fatima Brakta, PharmD, BCPS, AQ-ID; Ifeanyichukwu

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Head to Toe: Common infections in Hospital settings. Katya Calvo MD Medical Director of Antimicrobial Stewardship Division of Infectious Diseases

Head to Toe: Common infections in Hospital settings. Katya Calvo MD Medical Director of Antimicrobial Stewardship Division of Infectious Diseases Head to Toe: Common infections in Hospital settings Katya Calvo MD Medical Director of Antimicrobial Stewardship Division of Infectious Diseases Objectives To identify at least one common infection in

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

Antibiotic Update 2015

Antibiotic Update 2015 Antibiotic Update 2015: Disclosures Antibiotic Update 2015 No Financial Conflicts of Interest Shireesha Dhanireddy, MD 23 April 2015 Current Concepts in Drug Therapy Antibiotic Update 2015: Outline Cystitis

More information

OCTOBER 2017 DRUG ANTIBIOTICS CELLULITIS IN CHILDREN

OCTOBER 2017 DRUG ANTIBIOTICS CELLULITIS IN CHILDREN OCTOBER 2017 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.

More information

Antibiotic Stewardship in LTC What does this mean?

Antibiotic Stewardship in LTC What does this mean? Antibiotic Stewardship in LTC What does this mean? Kieran Moore FCFP,FRCPC, Diane Lu CCFP KFLA Public Health Disclosure The findings and conclusions represent those of the presenter and may not necessarily

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship

General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship Facilitator instructions: Read through the facilitator notes and make note of discussion points for each

More information

A. Incision and drainage alone B. Incision and drainage plus oral anti-mrsa antimicrobial agent C. Oral anti-mrsa antimicrobial agent

A. Incision and drainage alone B. Incision and drainage plus oral anti-mrsa antimicrobial agent C. Oral anti-mrsa antimicrobial agent Update: 2011 IDSA MRSA Treatment Guidelines Skin and soft tissue infections (SSTIs) Necrotizing fasciitis Animal bites Other skin and soft tissue infections Catherine Liu, M.D. Assistant Clinical Professor

More information

Optimize Durations of Antimicrobial Therapy

Optimize Durations of Antimicrobial Therapy Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

Cellulitis and Abscess: ED Phase v 1.1

Cellulitis and Abscess: ED Phase v 1.1 Cellulitis and Abscess: ED Phase v 1.1 Executive Summary Test Your Knowledge PHASE I (E.D.) Explanation of Evidence Ratings Summary of Version Changes! Labs if systemic illness or necrotizing fasciitis

More information

Diagnosis and Management of Skin and Soft-tissue Infections

Diagnosis and Management of Skin and Soft-tissue Infections Diagnosis and Management of Skin and Soft-tissue Infections Skin and soft tissue infections (SSTIs), are referred as skin and skin structure infections. These infections also represent a group of infections

More information

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required

More information

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING HIP AND KNEE ARTHROPLASTY

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING HIP AND KNEE ARTHROPLASTY Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING HIP AND KNEE ARTHROPLASTY FINAL Working Group: Dominik Mertz (Chair) Elizabeth Henderson, Johan

More information

An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?

An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? Dr. Andrew Morris Antimicrobial Stewardship ProgramMt. Sinai Hospital University Health Network amorris@mtsinai.on.ca andrew.morris@uhn.ca

More information

One-Hit Wonders: A New Era of Antibiotics?

One-Hit Wonders: A New Era of Antibiotics? One-Hit Wonders: A New Era of Antibiotics? Patrick Wieruszewski, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds November 1, 2016 2016 MFMER slide-1 Objectives Identify advantages and disadvantages

More information

4/28/11. Update: 2011 IDSA MRSA Treatment Guidelines. Necrotizing fasciitis Animal bites Other skin and soft tissue infections

4/28/11. Update: 2011 IDSA MRSA Treatment Guidelines. Necrotizing fasciitis Animal bites Other skin and soft tissue infections Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Update: 2011 IDSA MRSA Treatment Guidelines Skin and soft tissue infections (SSTIs)

More information

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes

More information

Symptoms of cellulitis (n=396) %

Symptoms of cellulitis (n=396) % Cellulitis and lymphoedema Vaughan Keeley May 2012 What is cellulitis? - also called erysipelas, acute inflammatory episodes etc. - bacterial infection of skin + subcutaneous tissues - more common in people

More information

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings

More information

2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY

2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY FINAL Working Group: E. Henderson, M. John, I. Davis, S. Dunford,

More information

Simplicef is Used to Treat Animals with Skin Infections

Simplicef is Used to Treat Animals with Skin Infections Simplicef is Used to Treat Animals with Skin Infections PRODUCT INFO Simplicef tablets are a semi-synthetic cephalosporin antibiotic cefpodoxime proxetil used to cure infections caused by the susceptible

More information

St. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report

St. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report St. Joseph s General Hospital Vegreville and Mary Immaculate Care Centre Antimicrobial Stewardship Report January to June 217 Introduction Antibiotics are among the most commonly prescribed medications

More information

Antibiotic Stewardship NOW!

Antibiotic Stewardship NOW! Antibiotic Stewardship NOW! The More We Use Antibiotics, the More We Lose Antibiotics Nick Zaksek Pharm D. BCPS AQ ID PADONA 2019 Antimicrobial Stewardship Coordinated interventions designed to improve

More information

SASKATCHEWAN REGISTERED NURSES ASSOCIATION. RNs WITH ADDITIONAL AUTHORIZED PRACTICE CLINICAL DECISION TOOL DECEMBER 1, 2016 MASTITIS ADULT & PEDIATRIC

SASKATCHEWAN REGISTERED NURSES ASSOCIATION. RNs WITH ADDITIONAL AUTHORIZED PRACTICE CLINICAL DECISION TOOL DECEMBER 1, 2016 MASTITIS ADULT & PEDIATRIC DEFINITION An inflammatory condition of the breast, possibly accompanied by infection and usually associated with lactation. Can be seen in non-lactating clients. IMMEDIATE CONSULTATION REQUIRED IN THE

More information